Skip to contentL
Lisata Therapeutics, Inc.
L
LSTALisata Therapeutics, Inc. Released Aug 4, 2022, after the close
10-Q filed Aug 4, 2022, 35 days after period end · 0000320017-22-000057
Q2 2021 · 10-Q
Revenue—
Net Income-$6.63M-$6.63MN/M vs Q2 2020N/M vs Q1 2021 EPS Diluted
No earnings release is on file for this quarter. Its figures came with the 10-Q.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lisata Therapeutics, Inc. · CIK 320017 · Engraved from SEC EDGAR
-$1.64-$1.64N/M vs Q2 2020N/M vs Q1 2021 Operating Income-$6,720,000N/M Operating Cash Flowderived-$5,062,000N/M Filing lag
ended Jun 30, 2022 · filed Aug 4, 2022 · 35 d after period end